The Indian anti-obesity market is set for a significant pricing transformation as the patent for semaglutide, the key ingredient in blockbuster weight-loss medications, expires on March 20, 2026. This development coincides with a $2 billion price war in the global market, as Novo Nordisk plans to slash U.S. list prices for Ozempic and Wegovy by up to 50% starting next year. According to reports from The Times of India, this global price pressure is creating a 5-13% sales decline forecast for 2026, with the company's shares plunging over 17% following the announcement. The Indian market will see over six-to-seven players enter following the patent expiry, including major pharmaceutical companies such as Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco Pharma, who are expected to launch affordable generic versions on March 21, 2026.
The nearly ₹1,400 crore weight-loss market is positioned for substantial growth following the patent expiry. As reported by The Times of India, analysts expect the market to double within a year due to increased competition and lower pricing. The GLP-1 segment alone has already surpassed ₹1,000 crore in annual sales in India, demonstrating strong market demand. The broader antidiabetic therapy market demonstrated strong performance with over 15% growth in January, led by rapid uptake of innovative therapies. Pharmarack research data shows that Eli Lilly's Mounjaro achieved ₹112 crore in sales, contributing to the market expansion. However, the global market faces additional challenges as 1.5 million Americans are already taking cheaper, unapproved compounded versions of semaglutide, with telehealth providers now planning to sell compounded versions of new oral medications.
Generic versions of semaglutide are expected to be priced significantly lower, initially 30-50% less than innovator brands, with potential price reductions reaching 70-75% over time. According to The Times of India, this pricing represents substantial savings for patients compared to current innovator brand prices. The global price war is being driven by dual competition: Eli Lilly's superior products have overtaken Novo Nordisk in the weight-loss race, while cheaper, unapproved compounded versions are already being used by an estimated 1.5 million Americans. Novo Nordisk's new oral Wegovy pill is gaining rapid adoption with 170,000 people trying it since launch in early January, achieving 15 times faster uptake than the injectable version. However, the pill is being sold at a $149 starter dose as part of a deal with the White House, directly contributing to the company's financial challenges.
The Trump administration is taking aggressive action against unauthorized semaglutide products, with the FDA referring Hims to the Department of Justice for potential legal violations after the company announced plans to sell a $49 compounded version of Wegovy. As reported by Reuters, Hims backed off the plan after the FDA indicated it would take enforcement action, with HHS general counsel Mike Stuart stating the agency's actions were motivated by protecting pharmaceutical companies' investments in traditional FDA approval and ensuring product safety. Drugmakers have argued that some compounders are illegally marketing unapproved copies of their products, with the FDA able to take enforcement actions when compounders essentially sidestep the federal drug approval process. The administration could pursue injunctions or fines against Hims for violating the Food, Drug and Cosmetic Act, though attorneys suggest Hims' quick retreat may limit legal options.
Sun Pharma's MD Kirti Ganorkar confirmed the company's commitment to launching generic semaglutide on day-one, stating their position as India's largest pharmaceutical company with leadership in cardiometabolic therapies. The company plans to offer brands in easy-to-use prefilled pen format with sufficient supply to meet Indian demand. Dr Reddy's Laboratories has received approval for a generic Ozempic for type 2 diabetes and aims to launch 12 million pens in its first year. Zydus Lifesciences is developing a differentiated injectable version, while the collaboration between Eris Lifesciences and Natco Pharma highlights strategic alliances forming in anticipation of the market surge. Novo Nordisk is using volume and lower prices to retain patients, but this approach is eroding pricing power and profitability as the company enters a price war it cannot afford to lose.
Key Indian players are entering this high-stakes market with varied financial profiles. Sun Pharma shows strong operational metrics like ROCE of 18.97% and ROE of 15.66%, but its P/E ratio is elevated, ranging from 33.9 to 103.36 as of early 2026, with reported poor 3-year revenue growth. Dr Reddy's trades at a P/E of approximately 18.36, which appears reasonable compared to peers. Zydus Lifesciences shows strong revenue and profit growth with a healthy ROE of 31.29% and P/E around 19.55. Natco Pharma exhibits one of the lowest P/E ratios at 10.36, signaling potential undervaluation, coupled with strong profit growth and being nearly debt-free. The intense competition could lead to margin compression across the board, especially for companies that fail to achieve economies of scale or differentiate their offerings beyond basic generics. Novo Nordisk's forecast for its first annual sales decline since 2017 highlights the structural challenges facing the global market leader.
The entry of generic semaglutide is expected to unlock significant latent demand and provide strong market expansion, according to OneSource Specialty Pharma CEO Neeraj Sharma. The Indian pharmaceutical sector overall is projected for 7-9% growth in FY26, driven by domestic demand and European markets, though the US market faces headwinds from pricing pressures. Analysts project the market could grow 10-fold over the next few years as competition intensifies, with lower-priced generics expected to sharply widen access to these weight-loss treatments. The rush to capture market share may also lead to aggressive spending on sales forces and marketing, potentially offsetting some of the cost advantages gained from generic production. The global market faces additional complexity as patent expiries in several markets outside the U.S. will also weigh on sales, compounding the challenges for established players like Novo Nordisk.
